Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome

C. Gambacorti Passerini, M. Cortellaro, E. Cofrancesco, C. Boschetti, E. Pogliani, G. Alessio, N. Semeraro, L. Mussoni, M. B. Donati

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with the hypereosinophilic syndrome (HES) are at increased risk of thrombosis and have signs of fibrin deposition in the myocardial cavity; the pathogenesis of these complications is still unknown. We have studied a 51-year-old man affected by HES with heart, lung, skin, and gastrointestinal involvement. Routine laboratory parameters of the hemostatic system were normal with the exception of blood fibrinolytic activity. The latter was evaluated by both diluted blood clot lysis time and euglobulin lytic activity on fibrin plates before and after 10 min venous occlusion. The fibrinolytic activity measured on four occasions during a 3-month period, was impaired both in basal conditions and following venous occlusion. Platelet studies on two different occasions before and during therapy showed spontaneous agents, replaced platelet regeneration time and increased plasma β-thromboglobulin concentration. The patient's polymorphonuclear cells (more than 75% eosinophils) were devoid of any procoagulant activity (PCA). Instead, patient's mononuclear cells studied before therapy generated significantly higher PCA on stimulation by endotoxin than cells from control subjects. The procoagulant response to endotoxin decreased markedly during therapy. The observed abnormalities could, at least partially, contribute to fibrin deposition in HES.

Original languageEnglish
Pages (from-to)32-37
Number of pages6
JournalHaemostasis
Volume19
Issue number1
Publication statusPublished - 1989

Fingerprint

Hypereosinophilic Syndrome
Fibrin
Endotoxins
Thrombosis
Blood Platelets
Fibrin Clot Lysis Time
Serum Globulins
Hemostatics
Eosinophils
Regeneration
Therapeutics
Lung
Skin

ASJC Scopus subject areas

  • Hematology

Cite this

Gambacorti Passerini, C., Cortellaro, M., Cofrancesco, E., Boschetti, C., Pogliani, E., Alessio, G., ... Donati, M. B. (1989). Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome. Haemostasis, 19(1), 32-37.

Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome. / Gambacorti Passerini, C.; Cortellaro, M.; Cofrancesco, E.; Boschetti, C.; Pogliani, E.; Alessio, G.; Semeraro, N.; Mussoni, L.; Donati, M. B.

In: Haemostasis, Vol. 19, No. 1, 1989, p. 32-37.

Research output: Contribution to journalArticle

Gambacorti Passerini, C, Cortellaro, M, Cofrancesco, E, Boschetti, C, Pogliani, E, Alessio, G, Semeraro, N, Mussoni, L & Donati, MB 1989, 'Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome', Haemostasis, vol. 19, no. 1, pp. 32-37.
Gambacorti Passerini C, Cortellaro M, Cofrancesco E, Boschetti C, Pogliani E, Alessio G et al. Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome. Haemostasis. 1989;19(1):32-37.
Gambacorti Passerini, C. ; Cortellaro, M. ; Cofrancesco, E. ; Boschetti, C. ; Pogliani, E. ; Alessio, G. ; Semeraro, N. ; Mussoni, L. ; Donati, M. B. / Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome. In: Haemostasis. 1989 ; Vol. 19, No. 1. pp. 32-37.
@article{84998431ce8b4f1a94d82d677e3d554b,
title = "Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome",
abstract = "Patients with the hypereosinophilic syndrome (HES) are at increased risk of thrombosis and have signs of fibrin deposition in the myocardial cavity; the pathogenesis of these complications is still unknown. We have studied a 51-year-old man affected by HES with heart, lung, skin, and gastrointestinal involvement. Routine laboratory parameters of the hemostatic system were normal with the exception of blood fibrinolytic activity. The latter was evaluated by both diluted blood clot lysis time and euglobulin lytic activity on fibrin plates before and after 10 min venous occlusion. The fibrinolytic activity measured on four occasions during a 3-month period, was impaired both in basal conditions and following venous occlusion. Platelet studies on two different occasions before and during therapy showed spontaneous agents, replaced platelet regeneration time and increased plasma β-thromboglobulin concentration. The patient's polymorphonuclear cells (more than 75{\%} eosinophils) were devoid of any procoagulant activity (PCA). Instead, patient's mononuclear cells studied before therapy generated significantly higher PCA on stimulation by endotoxin than cells from control subjects. The procoagulant response to endotoxin decreased markedly during therapy. The observed abnormalities could, at least partially, contribute to fibrin deposition in HES.",
author = "{Gambacorti Passerini}, C. and M. Cortellaro and E. Cofrancesco and C. Boschetti and E. Pogliani and G. Alessio and N. Semeraro and L. Mussoni and Donati, {M. B.}",
year = "1989",
language = "English",
volume = "19",
pages = "32--37",
journal = "Haemostasis",
issn = "0301-0147",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome

AU - Gambacorti Passerini, C.

AU - Cortellaro, M.

AU - Cofrancesco, E.

AU - Boschetti, C.

AU - Pogliani, E.

AU - Alessio, G.

AU - Semeraro, N.

AU - Mussoni, L.

AU - Donati, M. B.

PY - 1989

Y1 - 1989

N2 - Patients with the hypereosinophilic syndrome (HES) are at increased risk of thrombosis and have signs of fibrin deposition in the myocardial cavity; the pathogenesis of these complications is still unknown. We have studied a 51-year-old man affected by HES with heart, lung, skin, and gastrointestinal involvement. Routine laboratory parameters of the hemostatic system were normal with the exception of blood fibrinolytic activity. The latter was evaluated by both diluted blood clot lysis time and euglobulin lytic activity on fibrin plates before and after 10 min venous occlusion. The fibrinolytic activity measured on four occasions during a 3-month period, was impaired both in basal conditions and following venous occlusion. Platelet studies on two different occasions before and during therapy showed spontaneous agents, replaced platelet regeneration time and increased plasma β-thromboglobulin concentration. The patient's polymorphonuclear cells (more than 75% eosinophils) were devoid of any procoagulant activity (PCA). Instead, patient's mononuclear cells studied before therapy generated significantly higher PCA on stimulation by endotoxin than cells from control subjects. The procoagulant response to endotoxin decreased markedly during therapy. The observed abnormalities could, at least partially, contribute to fibrin deposition in HES.

AB - Patients with the hypereosinophilic syndrome (HES) are at increased risk of thrombosis and have signs of fibrin deposition in the myocardial cavity; the pathogenesis of these complications is still unknown. We have studied a 51-year-old man affected by HES with heart, lung, skin, and gastrointestinal involvement. Routine laboratory parameters of the hemostatic system were normal with the exception of blood fibrinolytic activity. The latter was evaluated by both diluted blood clot lysis time and euglobulin lytic activity on fibrin plates before and after 10 min venous occlusion. The fibrinolytic activity measured on four occasions during a 3-month period, was impaired both in basal conditions and following venous occlusion. Platelet studies on two different occasions before and during therapy showed spontaneous agents, replaced platelet regeneration time and increased plasma β-thromboglobulin concentration. The patient's polymorphonuclear cells (more than 75% eosinophils) were devoid of any procoagulant activity (PCA). Instead, patient's mononuclear cells studied before therapy generated significantly higher PCA on stimulation by endotoxin than cells from control subjects. The procoagulant response to endotoxin decreased markedly during therapy. The observed abnormalities could, at least partially, contribute to fibrin deposition in HES.

UR - http://www.scopus.com/inward/record.url?scp=0024501443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024501443&partnerID=8YFLogxK

M3 - Article

C2 - 2522075

AN - SCOPUS:0024501443

VL - 19

SP - 32

EP - 37

JO - Haemostasis

JF - Haemostasis

SN - 0301-0147

IS - 1

ER -